Non-lethal weapons company Byrna (NASDAQ:BYRN) will be reporting earnings this Thursday morning. Here’s what to expect.
Byrna met analysts’ revenue expectations last quarter, reporting revenues of $28.18 million, up 35.1% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ EBITDA estimates.
Is Byrna a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Byrna’s revenue to grow 24.8% year on year to $34.92 million, slowing from the 78.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.11 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Byrna has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Byrna’s peers in the aerospace and defense segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Boeing delivered year-on-year revenue growth of 57.1%, beating analysts’ expectations by 6.9%, and AAR reported revenues up 15.9%, topping estimates by 4.4%. Boeing traded down 2.8% following the results while AAR was up 2.1%.
Read our full analysis of Boeing’s results here and AAR’s results here.
There has been positive sentiment among investors in the aerospace and defense segment, with share prices up 8.5% on average over the last month. Byrna is down 22.7% during the same time and is heading into earnings with an average analyst price target of $39.70 (compared to the current share price of $13.37).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.